재고 위치

New Jersey, USA
Czech Republic, EU
Mumbai, India

* 재고 가용성에 따라 다름

Documentation

MSDS 다운로드

샘플 COA 다운로드

포함 사항: HPLC, MASS/LC-MS, 1H NMR, FT-IR, 함량, 구조 규명 보고서(SER), 그리고 제품에 따라 추가 분석 데이터가 제공됩니다.

136135-57-4Amphotericin B EP Impurity B

● 재고 있음

카탈로그 번호:	VL3210001
CAS 번호:	136135-57-4
분자식:	C48H75NO
분자량:	938.13 g/mol

견적 요청

RFQ 목록에 추가

에 대한 추가 정보 CAS 136135-57-4

모약물

Amphotericin B

IUPAC명

Amphotericin X1

약전 동의어

13-O-Methyl Amphotericin B

Other Synonyms

14,39-Dioxabicyclo[33.3.1]nonatriacontane Amphotericin B derivative; (1R,3S,5R,6R,9R,11R,15S,16R,17R,18S,19Z,21Z,23Z,25Z,27Z,29Z,31Z,33R,35S,36R,37S)-33-[(2R,3S,4S,5S,6R)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy-3,5,6,9,11,17,37-heptahydroxy-1-methoxy-15,16,18-trimethyl-13-oxo-14,39-dioxabicyclo[33.3.1]nonatriaconta-19,21,23,25,27,29,31-heptaene-36-carboxylic acid

InChI

InChI=1S/C31H40N6O9S2/c1-30(2)22(28(43)44)34-18(47-30)13-33-25(41)20(15-7-11-17(39)12-8-15)35-26(42)21(27-37-23(29(45)46)31(3,4)48-27)36-24(40)19(32)14-5-9-16(38)10-6-14/h5-12,18-23,27,34,37-39H,13,32H2,1-4H3,(H,33,41)(H,35,42)(H,36,40)(H,43,44)(H,45,46)/t18-,19+,20+,21+,22-,23-,27-/m0/s1

SMILES

O=C([C@@H]1N[C@H]([C@H](NC([C@H](N)C2=CC=C(O)C=C2)=O)C(N[C@H](C3=CC=C(O)C=C3)C(NC[C@@H]4SC(C)(C)[C@H](C(O)=O)N4)=O)=O)SC1(C)C)O

설명

Amphotericin B EP Impurity B known in pharmacopoeias 13-O-Methyl Amphotericin B is a thoroughly characterized reference standard. It meets strict regulatory standards including those set by USP EMA JP and BP. This product is crucial for use in Abbreviated New Drug Applications (ANDA) New Drug Applications (NDA) and the commercial production of Amphotericin B. Additionally it comes with a detailed Structure Elucidation Report (SER) ensuring its precision and dependability for a variety of analytical uses. It is an impurity of Amphotericin, it is a belongs to an antifungal class that used in the treatment of serious, life-threatening fungal infections.

References

Mesa-Arango, Ana C., et al. “It Only Takes One to Do Many Jobs: Amphotericin B as Antifungal and Immunomodulatory Drug.” Frontiers in Microbiology, vol. 3, 2012, www.ncbi.nlm.nih.gov/pmc/articles/PMC3441194/, 10.3389/fmicb.2012.00286.